Navigation Links
Auspex Initiates Phase 3 Trial of SD-809 in Huntington's Disease
Date:7/11/2013

LA JOLLA, Calif., July 11, 2013 /PRNewswire/ -- Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary movements (chorea) associated with Huntington's Disease (HD). Top-line data from the trial, designated the First-HD study, are expected in 2014.

(Logo: http://photos.prnewswire.com/prnh/20130627/MM40068LOGO)

"SD-809 is a deuterated form of tetrabenazine with pharmacokinetic properties that allow for more consistent blood levels and less frequent dosing.  This may lead to improved medication compliance and patient outcomes," said David A. Stamler, MD, Auspex Chief Medical Officer. "We are enthusiastic to be conducting this study in partnership with the Huntington Study Group, an international network of experienced clinical trial investigators at leading academic centers that care for HD patients and families."

First-HD, or "First time use of SD-809 in HD", is a randomized, double-blind, placebo-controlled study that will test the efficacy, safety and tolerability of SD-809 in the management of chorea symptoms in 90 HD patients who have not previously taken tetrabenazine.  The primary endpoint for the study will be Total Maximal Chorea (TMC) score. Secondary endpoints will include treatment success measurements based on patient and clinical global impressions of change. Participants will be involved in this trial for approximately four months. In parallel with First-HD, Auspex will be conducting an open-label study of SD‑809 in experienced tetrabenazine users and subjects who complete First-HD (Alternatives for Reducing Chorea in HD or ARC-HD Trial).

Principal Investigators for the First-HD study are Dr. Samuel Frank at Boston
'/>"/>

SOURCE Auspex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auspex Pharmaceuticals Receives U.S. Patent on Novel JAK Inhibitor SD-900
2. AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
3. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
4. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
7. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
8. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
9. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
10. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
11. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless ... Robert F. Doman , Executive Chairman and Interim ... Noble Financial Capital Markets, Tenth Annual Equity Conference. ... corporate presentation to prospective corporate partners and investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ... $2.92 per share, net to the seller in cash, ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 ... HTWR ), a leading innovator of less invasive, ... treatment of advanced heart failure, today announced that ... 2013 will be approximately $53 million, bringing expected ... "Our full-year revenue growth of 87% for ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... March 13, 2012  American Capital, Ltd. (Nasdaq: ... million, $20 million together with its affiliates, in the ... a medical device company focused on women,s health.   ... portfolio company Halt Medical as it continues to grow ...
... 2012  Janssen Research & Development, LLC today announced ... of ZYTIGA® (abiraterone acetate) plus prednisone for the ... metastatic castration-resistant prostate cancer (CRPC) who have not ... an international, randomized, double-blind, placebo controlled study that included ...
Cached Medicine Technology:American Capital and its Affiliates Invest $20 Million in Portfolio Company Halt Medical 2Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 2Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 3Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 4Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 5Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 6
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Art of Living Foundation of spiritual leader Sri Sri ... by 2008 that will be an "amalgamation of science ... Ravi Shankar Vidya Mandir (SSRVM) Trust, the educational wing ... memorandum of understanding with Ashok Tripathy, the secretary of ...
... a medical and health university to promote the study //of ... ,"The government will soon start the process of ... the university," Vishnoi told IANS, adding that the idea came ... ,"The need for introducing subjects like yoga and ...
... chances of getting cardiovascular, pulmonary, neurological, and endocrine ... according to a research published in the November ... Medicine. ,"This work is yet another ... relationships between mental and physical health," said Caroline ...
... papilloma virus (HPV), is the virus that causes cervical cancer ... uterus, known as cervix. It is transmitted sexually.// ... Plc's has introduced Cervarix, both vaccines, clinically been proven to ... potential are likely to be welcomed in rich countries but ...
... oral contraceptives taken on a long term basis to do away ... both safe and effective.The study// was published in the journal” Contraception”.,There ... the number of menstrual periods to four in a year. This ... to do away with menstrual periods altogether. ,"It ...
... the mutated form of a gene called Palladin causes ... the// disease is so deadly. The research project was ... professor of medicine, and supported by The Lustgarten Foundation, ... cancer is usually a fatal diagnosis. One of the ...
Cached Medicine News:Health News:Schizophrenics At Greater Risk Of Developing Chronic Diseases 2Health News:Vaccines For Cervical Cancer Will Soon Be Available In Developing Nations 2Health News:Team Discovers a Gene That Causes Familial Pancreatic Cancer 2Health News:Team Discovers a Gene That Causes Familial Pancreatic Cancer 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: